(CercleFinance.com) – genOway announces the creation of a joint venture in Shanghai (China), which will locally promote and sell its catalog of preclinical models in immuno-oncology.
genOway’s strategy through this joint venture is to develop a quality sales team capable of delivering to its Chinese customers the same strong scientific added value as that successfully provided in Western markets.
genOway will provide the joint venture with its immuno-oncology models and solutions as well as the associated scientific and technical expertise.
genOway will have 45% of the capital and a right of veto over the strategic choices of the joint venture.
For their part, the Chinese partners of the joint venture, from the field of MedTech, will bring their knowledge of the local market, their network and their ability to recruit and lead high-level scientific commercial teams (PhD expert).